Evaluation of Transrectal Perilesional Biopsy in Diagnosis of Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Prostate Cancer
Interventions
PROCEDURE

Transrectal perilesional/regional systematic biopsy (PB/RSB)

The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra) through transrectal prostate biopsy. The location of these nine cores depended on the shape and location of the suspicious lesion.

PROCEDURE

Combination of transrectal systematic biopsy and targeted biopsy

The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five transrectal targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core transrectal prostate biopsy.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT06482658 - Evaluation of Transrectal Perilesional Biopsy in Diagnosis of Prostate Cancer | Biotech Hunter | Biotech Hunter